|
FREE Cultural Competency Resources
Minority populations are more likely to develop CKD than non-minority populations. Studies show that African Americans, Native Americans, Hispanics and American Asians are, respectively, 4.5, 3.6, 2 and 1.6 times more likely to develop CKD than are Caucasians. Click here for free resources. |
|
CONTACT US
For resources or technical  assistance on the Chronic Kidney Disease Project, call 1.800.564.7490 and ask for a member of the CKD Team or email CKDTeam@fmqai.com. |
|
Order FREE Materials
Click on the image.  | |
|
Clinical Labs Report Additional Data to Aid in Detecting Kidney Disease
 The American Clinical Laboratory Association (ACLA), which represents approximately 70% of independent laboratory services throughout the U.S., made a recommendation in May that its members voluntarily calculate an eGFR and report this additional information when doctors order a serum creatinine.
According to the news release by ACLA, six states now mandate that clinical laboratories report eGFR when creatinine is ordered. These states include Louisiana, Michigan, Connecticut, Pennsylvania, New Jersey, and Tennessee.
To read the article, click here. |
|
|
|
Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease
 According to an article recently released by FMQAI, "There are currently more than 26 million American adults living with CKD, a number that continues to rise"(National Kidney Foundation.) A substantial and growing body of evidence has been published confirming the importance of either an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) in the treatment or prevention of a number of disease states. Both classes of drugs have been shown to slow the progression of kidney disease by significantly reducing proteinuria, delaying transition from micro- to macroalbuminuria and slowing the decline in glomerular filtration rate American Journal of Kidney Disease.)
The article provides information on dosing, adverse effects, and combination therapy. To read the article, click here. |
|
|
|
Medicare Learning Network Announces Availability of the 2009 PQRI and ePrescribing Program Web-based Training Course
 The Centers for Medicare & Medicaid Services (CMS) Medicare Learning Network (MLN) is pleased to announce that the Physician Quality Reporting Initiative (PQRI) and Electronic Prescribing Incentive Program (E-Prescribing) Web-based Training Course is now available.
The course provides information to physicians, health care professionals, and medical administrative staff on the completion, submission and maintenance of the documentation required to successfully participate in Physician Quality Reporting Initiative (PQRI) and Electronic Prescription Incentive (E-Prescribing) programs. The course offers continuing education credits; please see the course description page for the details.
The course can be accessed by going to http://www.cms.hhs.gov/MLNGenInfo on the CMS website and scrolling down to the “Related Links Inside CMS” section and selecting Web Based Training (WBT) Modules. Once on the web-based training module page, select the Physician Quality Reporting Initiative and Electronic Prescribing Incentive Program WBT from the list provided. |
|
|
|
The Medicare Quality Improvement Organization
 FMQAI serves as the Medicare Quality Improvement Organization and End Stage Renal Disease Network (ESRD Network 7) for Florida. With a strong reputation as a leader in facilitating change and collaboration, FMQAI implements projects and conducts case review activities to improve care across all settings, including dialysis and transplant facilities.
| |
